Poly(ADP-ribosyl)ation Regulation of Life and Death in the Nervous System
Overview
Authors
Affiliations
Poly(ADP-ribosyl)ation is required by multicellular eukaryotes to ensure genomic integrity under conditions of mild to moderate genotoxic stress. However, severe stress following acute neuronal injury causes overactivation of poly(ADP-ribose) polymerase-1, which results in unregulated poly(ADP-ribose) (PAR) synthesis and widespread neuronal cell death. Once thought to be a necrotic cell death resulting from energy failure, PARP-1 activation is now known to induce the nuclear translocation of apoptosis-inducing factor, which results in caspase-independent cell death. Conversely, poly(ADP-ribose) glycohydrolase, once thought to contribute to neuronal injury, now appears to have a protective role as demonstrated by recent studies utilizing gene disruption technology. Thus, the emerging mechanism dictating the fate of neurons appears to involve the regulation of PAR levels in neurons. Therefore, therapies targeting poly(ADP-ribosyl)ation in the treatment of neurodegenerative conditions such as stroke and Parkinson's disease are required to inhibit PAR synthesis and/or facilitate its degradation.
PARP-1-Associated Pathological Processes: Inhibition by Natural Polyphenols.
Maluchenko N, Feofanov A, Studitsky V Int J Mol Sci. 2021; 22(21).
PMID: 34768872 PMC: 8584120. DOI: 10.3390/ijms222111441.
Avoid the trap: Targeting PARP1 beyond human malignancy.
Kim C, Chen C, Yu Y Cell Chem Biol. 2021; 28(4):456-462.
PMID: 33657415 PMC: 8052287. DOI: 10.1016/j.chembiol.2021.02.004.
Verma D, Gupta S, Biswas J, Joshi N, Raju K, Wahajuddin M Neurotox Res. 2018; 34(2):198-219.
PMID: 29532444 DOI: 10.1007/s12640-018-9878-2.
Opportunities for the repurposing of PARP inhibitors for the therapy of non-oncological diseases.
Berger N, Besson V, Boulares A, Burkle A, Chiarugi A, Clark R Br J Pharmacol. 2017; 175(2):192-222.
PMID: 28213892 PMC: 5758399. DOI: 10.1111/bph.13748.
Mitochondrial Mechanisms of Neuronal Cell Death: Potential Therapeutics.
Dawson T, Dawson V Annu Rev Pharmacol Toxicol. 2017; 57:437-454.
PMID: 28061689 PMC: 11323062. DOI: 10.1146/annurev-pharmtox-010716-105001.